arsenic trioxide has been researched along with B-Cell Chronic Lymphocytic Leukemia in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boddu, P; Ferrajoli, A; Jain, N; Kadia, T; Pemmaraju, N; Ravandi, F; Schlette, E; Tang, G; Thakral, B; Wierda, W | 1 |
| Bao, JL; Feng, R; Huang, XJ; Jiang, Q; Lv, M; Qing, YZ; Zhang, XH; Zheng, XL; Zhu, HH | 1 |
| Aguilera-Montilla, N; Amigo-Jiménez, I; Bailón, E; García-Marco, JA; García-Pardo, A; Ugarte-Berzal, E | 1 |
| Amigo-Jiménez, I; García-Marco, JA; García-Pardo, A; Lozano-Santos, C; Nova-Gurumeta, S; Pérez-Sanz, N | 1 |
| Aguilera-Montilla, N; Amigo-Jiménez, I; Bailón, E; García-Marco, JA; García-Pardo, A; Terol, MJ | 1 |
| Aguilera-Montilla, N; Amigo-Jiménez, I; Bailón, E; García-Marco, JA; García-Pardo, A | 1 |
| Ahuja, HG; Bailey, HH; Chang, JE; Kahl, BS; Kim, K; Kolesar, JM; Rodriguez, GA; Sanchez, FA; Voorhees, PM; Werndli, J | 1 |
| Bairey, O; Shpilberg, O; Vanichkin, A | 1 |
| Biswas, S; Byrd, JC; Jarjoura, D; Mo, X; Mone, AP; Muthusamy, N; Vargo, M; Zhao, X | 1 |
| Escobar-Díaz, E; García-Marco, JA; García-Pardo, A; Hernández Del Cerro, M; Pandiella, A; Redondo-Muñoz, J; Terol, MJ | 1 |
| Goussetis, DJ; Platanias, LC | 1 |
| Carew, JS; Feng, L; Hileman, EO; Huang, P; Keating, MJ; Pelicano, H; Plunkett, W; Zhou, Y | 1 |
| Gibson, AD; Klem, J; Price, N; Reddy, GK | 1 |
| Andreeff, M; Carew, JS; Huang, P; Keating, MJ; McQueen, TJ; Pelicano, H; Plunkett, W | 1 |
| Asslaber, D; Greil, R; Hamacher, F; Heyder, C; Holler, C; Merkel, O; Papak, C; Prokesch, A; Scheideler, M; Stöcher, M; Tinhofer, I; Trajanoski, Z | 1 |
| Gabrilove, JL; Jakubowski, A; König, A; Pandolfi, PP; Rivi, R; Warrell, RP; Wrazel, L | 1 |
| Fujisawa, S; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Shigeno, K; Takeshita, A; Takeshita, K; Zhang, W | 1 |
1 trial(s) available for arsenic trioxide and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study.
Topics: Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Female; Glutathione; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Oxides; Safety | 2009 |
16 other study(ies) available for arsenic trioxide and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Promyelocytic, Acute; Male; Rituximab; Tretinoin | 2019 |
Arsenic trioxide induces apoptosis in B-cell chronic lymphocytic leukemic cells through down-regulation of survivin via the p53-dependent signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Down-Regulation; Gene Expression Regulation, Leukemic; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Oxides; Signal Transduction; Survivin; Tumor Suppressor Protein p53; Up-Regulation | 2013 |
Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide.
Topics: Aged; Aged, 80 and over; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Membrane; Down-Regulation; Drug Resistance, Neoplasm; Female; HEK293 Cells; Humans; Hyaluronan Receptors; Integrin alpha4beta1; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Matrix Metalloproteinase 9; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Oxides; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Transcription, Genetic; Up-Regulation; Vidarabine | 2014 |
Arsenic trioxide synergistically potentiates the cytotoxic effect of fludarabine in chronic lymphocytic leukemia cells by further inactivating the Akt and ERK signaling pathways.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Drug Synergism; Enzyme Inhibitors; Female; Growth Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; MAP Kinase Signaling System; Middle Aged; Oxides; Proto-Oncogene Proteins c-akt; Signal Transduction; Tumor Cells, Cultured; Vidarabine | 2015 |
Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Communication; Cell Line; Class I Phosphatidylinositol 3-Kinases; Coculture Techniques; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mesenchymal Stem Cells; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Oxides; Phosphorylation; Protein Kinase C beta; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Quinazolinones; RNA Interference; Signal Transduction; STAT3 Transcription Factor; Staurosporine; Time Factors; Transfection; Tumor Cells, Cultured; Tumor Microenvironment; Up-Regulation | 2015 |
Gene expression profile induced by arsenic trioxide in chronic lymphocytic leukemia cells reveals a central role for heme oxygenase-1 in apoptosis and regulation of matrix metalloproteinase-9.
Topics: Aged; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Heme Oxygenase-1; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Matrix Metalloproteinase 9; Middle Aged; Oxides; p38 Mitogen-Activated Protein Kinases; RNA Interference; Signal Transduction; Time Factors; Transcription Factor AP-1; Transcriptome; Transfection | 2016 |
Arsenic-trioxide-induced apoptosis of chronic lymphocytic leukemia cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Oxides; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2010 |
Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro.
Topics: Amino Acid Chloromethyl Ketones; Amitrole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Ascorbic Acid; B-Lymphocytes; Buthionine Sulfoximine; Catalase; Cell Line, Tumor; Cysteine Proteases; Cysteine Proteinase Inhibitors; Drug Evaluation, Preclinical; Drug Synergism; Enzyme Activation; Glutathione; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Oxidants; Oxidative Stress; Oxides; Reactive Oxygen Species | 2010 |
Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Survival; Dose-Response Relationship, Drug; Enzyme Activation; Female; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Potential, Mitochondrial; Microscopy, Confocal; Middle Aged; Oxides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA Interference; Signal Transduction; Tumor Cells, Cultured; Up-Regulation | 2010 |
Arsenic trioxide and the phosphoinositide 3-kinase/akt pathway in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Survival; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Lymphocytic, Chronic, B-Cell; Models, Biological; Oxides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Tumor Cells, Cultured; Up-Regulation | 2010 |
Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism.
Topics: 2-Methoxyestradiol; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cells, Cultured; Estradiol; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mitochondria; Oxides; Oxygen Consumption; Reactive Oxygen Species; Rotenone; Superoxides | 2003 |
45th Annual Meeting of the American Society of Hematology December 6-9, 2003.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematology; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Multiple Myeloma; Oxides; Prognosis; Protein-Tyrosine Kinases; Recurrence; Risk; Rituximab; Salvage Therapy; Thalidomide; Time Factors; ZAP-70 Protein-Tyrosine Kinase | 2004 |
Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzoquinones; Cytarabine; DNA; Drug Administration Schedule; Drug Antagonism; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; G1 Phase; HeLa Cells; HSP90 Heat-Shock Proteins; Humans; Jurkat Cells; Lactams, Macrocyclic; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Oxides; Sensitivity and Specificity; Structure-Activity Relationship; Tumor Cells, Cultured | 2006 |
Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Chromosome Deletion; Chromosomes, Human, Pair 17; Drug Resistance, Neoplasm; Enzyme Activation; Female; Free Radical Scavengers; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Oxidative Stress; Oxides; Poly(ADP-ribose) Polymerases; Prognosis; Reactive Oxygen Species; Superoxide Dismutase; Vidarabine | 2008 |
Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Cell Division; Cell Line, Transformed; Cell Survival; DNA Damage; DNA Fragmentation; Drug Screening Assays, Antitumor; Herpesvirus 4, Human; Humans; Kinetics; Leukemia, Lymphocytic, Chronic, B-Cell; Melarsoprol; Oxides; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Time Factors; Transcription, Genetic; Tumor Cells, Cultured | 1997 |
The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; Cell Survival; DNA Fragmentation; DNA, Neoplasm; Humans; Interphase; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Oxides; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 1998 |